Randomized, Phase II Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Patients With Advanced Melanoma (KEYNOTE 002)

Trial Profile

Randomized, Phase II Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Patients With Advanced Melanoma (KEYNOTE 002)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 May 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Dacarbazine; Paclitaxel; Temozolomide
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-002
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 12 Mar 2017 Results (n=315) of KEYNOTE-001,KEYNOTE-002, KEYNOTE-006 and one expanded acces phase II study assessing clinicopathological factors in PD-1 antibodies response published in the British Journal of Cancer.
    • 08 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top